Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 9/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | ESRRG | P62508 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5855583 | 0.81 | ESR1 (0.53) | ESR1ESR2 | |
| SCHEMBL6566287 | 0.81 | ESR1 (0.53) | ESR1ESR2 | |
| SCHEMBL5855586 | 0.81 | ESR1 (0.53) | ESR1ESR2 | |
| SCHEMBL5857082 | 0.74 | ESR1 (0.46) | NR5A1ESR1ESR2LTA4HESRRG | |
| SCHEMBL5857093 | 0.73 | NR5A1 (0.40) | NR5A1ESR1ESR2LTA4HESRRG | |
| SCHEMBL5855444 | 0.71 | ESR1 (0.45) | ESR1GPR119 | |
| SCHEMBL8193491 | 0.71 | ESR1 (0.45) | ESR1GPR119 | |
| SCHEMBL14559001 | 0.71 | SMN1; SMN2 (0.35) | ESR1ESR2 | |
| SCHEMBL5857365 | 0.70 | ESR1 (0.47) | NR5A1ESR1ESR2LTA4HESRRG | |
| SCHEMBL5854195 | 0.70 | ESR1 (0.37) | NR5A1ESR1ESR2LTA4HESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1086077-B1 | NOVEL ANTIESTROGENS, A METHOD FOR THE PRODUCTION THEREOF, AND THEIR PHARMACEUTICAL APPLICATION | SCHERING AG (DE) | 2004-04-07 | — | — | EP | claimed |
| US-20030162830-A1 | New antiestrogens, process for their production and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-28 | — | — | US | claimed |
| US-6166075-A | Antiestrogens, process for their production and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-12-26 | — | — | US | claimed |
| US-7074829-B2 | Antiestrogens, process for their production and their pharmaceutical use | SCHERING AG (DE) | 2006-07-11 | — | — | US | disclosed |
| EP-1086077-B1 | NOVEL ANTIESTROGENS, A METHOD FOR THE PRODUCTION THEREOF, AND THEIR PHARMACEUTICAL APPLICATION | SCHERING AG (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030162830-A1 | New antiestrogens, process for their production and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-28 | — | — | US | disclosed |
| US-6559181-B1 | A method to treat endometrial carcinoma, prostate cancer, or prostate hyperplasia comprising administering to a patient in need of such treatment an effective dose of a 3,4-Diphenyl-bicyclo(4.3.0)nonyl compound of formula I | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-06 | — | — | US | disclosed |
| EP-1086077-A1 | NOVEL ANTIESTROGENS, A METHOD FOR THE PRODUCTION THEREOF, AND THEIR PHARMACEUTICAL APPLICATION | Schering Aktiengesellschaft (DE) | 2001-03-28 | — | — | EP | disclosed |
| US-6166075-A | Antiestrogens, process for their production and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-12-26 | — | — | US | disclosed |
| WO-1999064393-A1 | NOVEL ANTIESTROGENS, A METHOD FOR THE PRODUCTION THEREOF, AND THEIR PHARMACEUTICAL APPLICATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162830-A1 | New antiestrogens, process for their production and their pharmaceutical use | CYP19A1, NR5A1, HSD17B11 | NR5A1 2/4885ESR1 6/4885ESR2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.